Back to top
more

Amgen (AMGN)

(Real Time Quote from BATS)

$285.22 USD

285.22
1,069,622

+0.55 (0.19%)

Updated Aug 7, 2025 01:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks News

Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva

Zacks Equity Research

J&J (JNJ) to Set the Stage for Pharma Sector Q4 Earnings

J&J's (JNJ) Pharma segment is expected to have performed above the market. It remains to be seen if sales improved in the Medical Devices segment in the fourth quarter.

Zacks Equity Research

Amgen (AMGN) Stock Moves -1.04%: What You Should Know

Amgen (AMGN) closed at $228.90 in the latest trading session, marking a -1.04% move from the prior day.

Zacks Equity Research

CytomX (CTMX) Gets FDA Nod to Begin Study in Solid Tumors

The FDA clears CytomX's (CTMX) investigational new drug application for CX-904, which is being developed for the treatment of advanced solid tumors.

Zacks Equity Research

Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know

Amgen (AMGN) closed at $235.36 in the latest trading session, marking a +1.95% move from the prior day.

Zacks Equity Research

BridgeBio (BBIO), Amgen Partner in Advanced Solid Tumors Study

BridgeBio (BBIO) forges an alliance with Amgen to evaluate their respective cancer drugs for the treatment of advanced solid tumors with KRAS G12C mutations.

Zacks Equity Research

Stock Market News for Jan 13, 2022

U.S. stocks closed slightly higher on Wednesday after data showed that inflation hit a four-decade high but came in largely in line with economists' expectations.

Zacks Equity Research

Biotech Stock Roundup: BIIB's AD Drug Update, AMGN's Drug Approval & Other Updates

Regulatory and other pipeline updates from Biogen (BIIB) and AMGN are among a few key highlights from the biotech sector during the past week.

Zacks Equity Research

Why the Earnings Surprise Streak Could Continue for Amgen (AMGN)

Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Amgen (AMGN) Gains As Market Dips: What You Should Know

Amgen (AMGN) closed at $230.37 in the latest trading session, marking a +1.36% move from the prior day.

Zacks Equity Research

Amgen's (AMGN) KRAS Inhibitor Gets Nod for Lung Cancer in EU

Amgen's (AMGN) Lumykras is the first targeted therapy approved for patients with KRAS G12C mutation in Europe.

Zacks Equity Research

Absci (ABSI) Inks Research Agreement With Merck, Stock Up

Absci (ABSI) signs a deal with Merck for using its AI-powered drug creation platform to produce enzymes for Merck's biomanufacturing applications with an option for the development of three novel drugs.

    Zacks Equity Research

    Should You Invest in the VanEck Biotech ETF (BBH)?

    Sector ETF report for BBH

    Zacks Equity Research

    Amgen (AMGN) Inks Multi-Target Deal to Make Protein Therapeutics

    Amgen (AMGN) signs a collaboration agreement with Generate Biomedicines to develop protein therapeutics across several therapeutic areas and multiple modalities.

    Sheraz Mian headshot

    Top Research Reports for Alphabet, salesforce & Starbucks

    Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), salesforce.com, inc. (CRM), and Starbucks Corporation (SBUX).

    Zacks Equity Research

    Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

    Smart Beta ETF report for IBB

    Zacks Equity Research

    Amgen (AMGN) Gains As Market Dips: What You Should Know

    In the latest trading session, Amgen (AMGN) closed at $227.84, marking a +0.51% move from the previous day.

    Zacks Equity Research

    Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know

    Amgen (AMGN) closed at $226.69 in the latest trading session, marking a +0.76% move from the prior day.

    Zacks Equity Research

    Should You Invest in the iShares Biotechnology ETF (IBB)?

    Sector ETF report for IBB

    Zacks Equity Research

    Amgen (AMGN) Gains As Market Dips: What You Should Know

    Amgen (AMGN) closed at $225.77 in the latest trading session, marking a +0.27% move from the prior day.

    Zacks Equity Research

    Ligand (LGND) Stock Surges 60% YTD: What's Driving the Rally?

    Strong demand for two of Ligand's (LGND) partnered drugs, AMGN's Krprolis and GILD's Veklury, is driving its royalties. This is likely to continue next year.

    Zacks Equity Research

    Biotech Stock Roundup: Regulatory Updates From BIIB, AMGN and NVAX & More

    Regulatory and other pipeline updates from Biogen (BIIB) and Novavax (NVAX) have been the biotech sector's few key highlights during the past week.

    Zacks Equity Research

    Amgen (AMGN) Stock Moves -1.13%: What You Should Know

    Amgen (AMGN) closed the most recent trading day at $219.99, moving -1.13% from the previous trading session.

    Zacks Equity Research

    Amgen, AstraZeneca's Asthma Drug Tezepelumab Gets FDA Nod

    Amgen (AMGN) and AstraZeneca's (AZN) Tezspire is the only biologic medicine approved by the FDA to treat severe asthma with no phenotype limitation and irrespective of biomarker levels.

    Zacks Equity Research

    Amgen (AMGN) Gains As Market Dips: What You Should Know

    Amgen (AMGN) closed at $213.74 in the latest trading session, marking a +1.11% move from the prior day.

    Zacks Equity Research

    Sanofi (SNY) Multiple Myeloma Phase III Study Meets Goal

    Sanofi's (SNY) phase III study on Sarclisa is the first to meet the primary endpoint of MRD negativity in transplant-eligible patients with newly diagnosed multiple myeloma.